alexa A Systematic Review Of Systemic Medications For The Treatment Of Melasma
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

International Conference on Infectious Diseases, Diagnostic Microbiology & Dermatologists Summit on Skin Infections
October 03-05, 2016 Vancouver, Canada

Linghong Zhou
University of Ottawa, Canada
Posters & Accepted Abstracts: J Infect Dis Ther
DOI: 10.4172/2332-0877.C1.018
Background & Aim: Melasma is a common disorder of pigmentation affecting people with darker skin types, most commonly Fitzpatrick skin types III-IV. Despite the large variety of treatment options available including solar exposure prevention, topical lightening agents, chemical peels, light-based and laser therapies, none have shown effective and sustained results, making melasma a challenging and difficult-to-treat condition. Recently, there has been increasing interest in systemic medications in the treatment of melasma. This systematic review evaluates the current state of evidence of these systemic medications in terms of efficacy and safety/ tolerability in the treatment of melasma. Methods: Multiple databases were systematically searched for randomized clinical trials (RCTs) evaluating the use of systemic medications for the treatment of melasma. A study was excluded if it did not satisfy RCT requirements, did not include melasma patients, did not report melasma specific outcome measures or consisted of fewer than 10 subjects. Results: Initial search yielded 629 papers evaluating a variety of treatments for melasma.After the application of inclusion and exclusion criteria, a total of 8 studies met eligibility criteria. Systemic medications evaluated include tranexamic acid (TA), Polypodium leucotomos extract (PLE), beta-carotenoid, melatonin and procyanidin. These agents have a generally beneficial effect with a minimal number and severity of adverse effects. Conclusion: Oral medications have been shown to be efficacious, safe and well-tolerated in the treatment of melasma. We recommend that dermatologists introduce systematic medications to their armamentarium for the treatment of melasma.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version